<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7781899\results\search\disease\results.xml">
  <result pre="evaluated for their cytotoxic activity against MDA-MB-231, MCF-7, HepG-2, HCT-116" exact="cancer" post="cell lines and EGFR inhibitory activity. The most active"/>
  <result pre="They proved their relative safety with high selectivity towards MDA-MB-231" exact="breast cancer" post="cell line. Measurement of the radiosensitizing activity for 5"/>
  <result pre="proved their relative safety with high selectivity towards MDA-MB-231 breast" exact="cancer" post="cell line. Measurement of the radiosensitizing activity for 5"/>
  <result pre="immunotherapy, targeted and combined therapy, are different strategies advocated for" exact="cancer" post="treatment4â€&quot;6. Protein kinases (PKs) play a pivotal role in"/>
  <result pre="the extracellular domain of the EGFR, activating kinases and promoting" exact="cancer" post="cell survival, invasiveness and drug resistance9,10. EGFR has a"/>
  <result pre="as targeted therapy as it aims at the differences between" exact="cancer" post="and normal cells and is characterized by its high"/>
  <result pre="the synthesized compounds were screened against MDA-MB-231, MCF-7, HepG-2, HCT-116" exact="cancer" post="cell lines and the most potent compounds were evaluated"/>
  <result pre="2.2. Biological evaluation 2.2.1. MTT assay MDA-MB-231, MCF-7, HepG-2, HCT-116" exact="cancer" post="cell lines and MCF-10A normal cells were obtained from"/>
  <result pre="panel of cell lines MDA-MB-231, MCF-7, HepG-2 and HCT-116 human" exact="cancer" post="cell lines derived from breast, liver and colon tumors."/>
  <result pre="receptor. 3.2.3. Radiosensitizing activity Radiotherapy is second to surgery in" exact="cancer" post="treatment. The major drawback of radiotherapy is its inability"/>
  <result pre="IC50â€‰ Table 3. IC50 of compounds 5 and 6 on" exact="cancer" post="cell lines after being subjected to irradiation. Cpd no."/>
  <result pre="showed variable anticancer activity against MDA-MB-231, MCF-7, HepG-2 and HCT-116" exact="cancer" post="cell lines and EGFR inhibitory activity comparable to erlotinib."/>
  <result pre="6 were the most promising in this series towards the" exact="cancer" post="cell lines and EGFR. Compounds 5 and 6 were"/>
  <result pre="they displayed radiosensitizing activity through their ability to sensitize the" exact="cancer" post="cells to the lethal effect of gamma irradiation. The"/>
  <result pre="1PeitzschC, PerrinR, HillRP, et al.Hypoxia as a biomarker for radioresistant" exact="cancer" post="stem cells. Int J Radiat Biol2014;90:636â€&quot;52.24844374 2SugrueT, LowndesNF, CeredigR.Hypoxia"/>
  <result pre="BournePE.Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the" exact="cancer" post="ecosystem. Front Pharmacol2015;6:209â€&quot;14.26441664 6El EllaDAA, GhorabMM, HeibaHI, SolimanAM.Synthesis of"/>
  <result pre="in cancer. Cancers2015;7:1758â€&quot;84.26404379 9BakerSJ, ReddyEP, MedicineP.Targeted inhibition of kinases in" exact="cancer" post="therapy. MT Sinai J Med2010;77:573â€&quot;86.21105121 10FlynnJF, WongC, WuJM.Anti-EGFR therapy:"/>
  <result pre="WongC, WuJM.Anti-EGFR therapy: mechanism and advances in clinical efficacy in" exact="breast cancer." post="J Oncol2009;2009:526963.19390622 11YewaleC, BaradiaD, VhoraI, et al.Epidermal growth factor"/>
 </snippets>
</snippetsTree>
